PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|March 2, 2017
- Pharmaceutical Technology-03-02-2017
- Volume 41
- Issue 3
Loading Bench for Cold-Chain Management
The OCEASOFT Loading Bench is an innovation for cold-chain monitoring management for transportation and high-volume shipment.
The OCEASOFT Loading Bench is an innovation for cold-chain monitoring management for transportation and high-volume shipment. The bench programs temperature datalogger missions with sensor reading intervals and alarm limits. The bench also performs a series of tests to verify hardware and battery level on dataloggers. The tool offers the ability to set how and when temperature monitoring begins, at a specific temperature, date or time, or manually. The loading bench includes an application for configuring missions and storing templates. The bench also transfers each datalogger’s configuration information to the cloud automatically. The loading bench will be available in Q2 2017.
Articles in this issue
over 9 years ago
Understanding Containmentover 9 years ago
International Trade Issues Threaten Global Pharma Operationsover 9 years ago
Oral Delivery of Biologic APIs: The Challenge Continuesover 9 years ago
Covering Global Regulations in a Quality Systemover 9 years ago
Risk-Based Predictive Stability–An Industry Perspectiveover 9 years ago
Quality Agreements:Managing Global Relationshipsover 9 years ago
Achieving Manufacturing Excellenceover 9 years ago
Mixers for Blending ApplicationsRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.